ClinVar Miner

Submissions for variant NM_001182.5(ALDH7A1):c.834G>A (p.Val278=)

gnomAD frequency: 0.00004  dbSNP: rs201948406
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 9
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000255917 SCV000321394 pathogenic not provided 2023-07-28 criteria provided, single submitter clinical testing Published functional studies demonstrate a damaging effect, suggesting this variant leads to abnormal gene splicing (Salomons et al., 2007); This variant is associated with the following publications: (PMID: 23022070, 22529283, 20554659, 19128417, 24122892, 17721876, 26026794, 27438048, 27324284, 23430810, 28973083, 29852413, 24748525, 20814824, 30043187, 31589614, 35782612, 31440721)
Invitae RCV000019618 SCV000640330 pathogenic Pyridoxine-dependent epilepsy 2024-01-15 criteria provided, single submitter clinical testing This sequence change affects codon 278 of the ALDH7A1 mRNA. It is a 'silent' change, meaning that it does not change the encoded amino acid sequence of the ALDH7A1 protein. RNA analysis indicates that this variant induces altered splicing and may result in an absent or disrupted protein product. This variant is present in population databases (rs201948406, gnomAD 0.01%). This variant has been observed in individual(s) with pyridoxine-dependent epilepsy (PMID: 17721876, 19128417, 20554659, 20814824, 22529283, 23022070, 23430810, 24122892, 27438048). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. This variant is also known as c.750G>A. ClinVar contains an entry for this variant (Variation ID: 18002). Studies have shown that this variant results in cryptic splice site activation and introduces a premature termination codon (PMID: 17721876). The resulting mRNA is expected to undergo nonsense-mediated decay. For these reasons, this variant has been classified as Pathogenic.
Eurofins Ntd Llc (ga) RCV000255917 SCV000703760 pathogenic not provided 2016-12-27 criteria provided, single submitter clinical testing
Elsea Laboratory, Baylor College of Medicine RCV000019618 SCV001424278 pathogenic Pyridoxine-dependent epilepsy 2020-04-01 criteria provided, single submitter clinical testing
Ambry Genetics RCV002433461 SCV002678553 likely pathogenic Inborn genetic diseases 2018-01-31 criteria provided, single submitter clinical testing The c.834G>A variant (also known as p.V278V), located in coding exon 9, results from a G to A substitution at nucleotide position 834 of the ALDH7A1 gene. This nucleotide substitution does not change the amino acid at codon 278. This nucleotide position is well conserved in available vertebrate species. This alteration has been detected in the homozygous and compound heterozygous state with other ALDH7A1 variants in several individuals with diagnoses of pyridoxine-dependent epilepsy (PDE) (Salomons GS et al. Ann. Neurol., 2007 Oct;62:414-8; Mercimek-Mahmutoglu S et al. Pediatrics, 2012 May;129:e1368-72; Proudfoot M et al. JIMD Rep, 2013 Mar;10:103-6; Coughlin CR et al. Mol. Genet. Metab. May;116:35-43; Yuzyuk T et al. Mol. Genet. Metab., 2016 07;118:167-72). In one study, authors isolated RNA from a homozygous individual to show that this alteration preferentially uses a cryptic donor splice site resulting in an out of frame deletion in exon 9 which leads to the p.Val250Glyfs*23 frameshift (Salomons GS et al. Ann. Neurol., 2007 Oct;62:414-8). Of note, this alteration is often called p.V250V (c.750G>A) in the literature. Using two different splice site prediction tools, this alteration is predicted by ESEfinder to create a new alternate splice donor site, but BDGP does not predict the creation of a non-native donor site, nor a deleterious effect on splicing; however, direct evidence is unavailable. Based on the majority of available evidence to date, this variant is likely to be pathogenic.
Genome-Nilou Lab RCV000019618 SCV004049190 likely pathogenic Pyridoxine-dependent epilepsy 2023-04-11 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000019618 SCV004242018 pathogenic Pyridoxine-dependent epilepsy 2023-12-08 criteria provided, single submitter clinical testing Variant summary: ALDH7A1 c.834G>A alters a non-conserved nucleotide resulting in a synonymous change. Several computational tools predict a significant impact on normal splicing: Four predict the variant strengthens a cryptic 5' donor site. At least one publication reports experimental evidence that this variant affects mRNA splicing (Salomons_2007). The variant allele was found at a frequency of 5.6e-05 in 251486 control chromosomes (gnomAD). This frequency is not significantly higher than estimated for a pathogenic variant in ALDH7A1 causing Pyridoxine-Dependent Epilepsy (5.6e-05 vs 0.0018), allowing no conclusion about variant significance. c.834G>A (also known as c.750G>A. ) has been reported in the literature in multiple individuals affected with Pyridoxine-Dependent Epilepsy (examples: Salomons_2007 and Marguet_2016). These data indicate that the variant is very likely to be associated with disease. The following publications have been ascertained in the context of this evaluation (PMID: 17721876, 27438048). Six submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. All submitters classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
OMIM RCV000019618 SCV000039916 pathogenic Pyridoxine-dependent epilepsy 2007-10-01 no assertion criteria provided literature only
GeneReviews RCV000019618 SCV001775554 not provided Pyridoxine-dependent epilepsy no assertion provided literature only The 2nd most common pathogenic variant, accounting for 5.4% of pathogenic variants

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.